Drug Profile


Alternative Names: E-2006; LEM 10; LEM 5

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Inc
  • Developer Eisai Inc; Purdue Pharma
  • Class Cyclopropanes; Hypnosedatives; Pyridines; Pyrimidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Orexin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Insomnia
  • Phase II Circadian rhythm sleep disorders

Most Recent Events

  • 19 Apr 2017 Phase-I clinical trials in Insomnia (In volunteers) in Canada (PO) (NCT03158025)
  • 08 Nov 2016 Eisai plans three phase III trials of lemborexant in Insomnia
  • 01 Nov 2016 Phase-III clinical trials in Insomnia (In adults, In the elderly) in Canada (PO) (NCT02952820)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top